Form 8-K - Current report:
SEC Accession No. 0001213900-25-039783
Filing Date
2025-05-06
Accepted
2025-05-05 17:43:44
Documents
15
Period of Report
2025-05-02
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0240955-8k_emmaus.htm   iXBRL 8-K 30721
2 LETTER DATED MAY 5, 2025 FROM MARCUM LLP TO THE SECURITIES AND EXCHANGE COMMISSI ea024095501ex16-1_emmaus.htm EX-16.1 3175
3 GRAPHIC ex16-1_001.jpg GRAPHIC 4018
  Complete submission text file 0001213900-25-039783.txt   209923

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE emma-20250502.xsd EX-101.SCH 3029
5 XBRL PRESENTATION FILE emma-20250502_pre.xml EX-101.PRE 22368
6 XBRL LABEL FILE emma-20250502_lab.xml EX-101.LAB 34239
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0240955-8k_emmaus_htm.xml XML 3359
Mailing Address 21250 HAWTHORNE BOULEVARD, SUITE 800 TORRANCE CA 90503
Business Address 21250 HAWTHORNE BOULEVARD, SUITE 800 TORRANCE CA 90503 310-214-0065
Emmaus Life Sciences, Inc. (Filer) CIK: 0000822370 (see all company filings)

EIN.: 870419387 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35527 | Film No.: 25914373
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)